---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-135669"
form_type: "8-K"
ticker: "AXSM"
cik: "0001579428"
company_name: "Axsome Therapeutics, Inc."
filed_at: "2026-04-01T23:59:59+00:00"
generated_at: "2026-05-15T07:58:33.577830+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Axsome acquires global rights to PDE10A inhibitor balipodect from Takeda

## Summary
- Obtained exclusive worldwide rights to balipodect, a selective PDE10A inhibitor, from Takeda.
- Balipodect completed a 164-patient Phase 2 trial in schizophrenia; safety profile established in over 360 individuals.
- Axsome plans to start Phase 3-enabling activities for schizophrenia in 2026 and also target Tourette syndrome.
- Takeda received an upfront payment and is eligible for development, regulatory, and commercial milestones plus royalties.

## SEC filing metadata
- accession: 0001193125-26-135669
- form_type: 8-K
- ticker: AXSM
- cik: 0001579428
- company_name: Axsome Therapeutics, Inc.
- filed_at: 2026-04-01T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1579428/000119312526135669/0001193125-26-135669-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1579428/000119312526135669/axsm-20260401.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-135669
- JSON: https://secwatch.observer/filing/0001193125-26-135669.json
- Plain text: https://secwatch.observer/filing/0001193125-26-135669.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.